Success all round for Cancer Research UK supported spinouts at the OBN annual awards

The OBN Annual Awards proved a night of big success for Cancer Research UK, with the 10th anniversary celebrating innovation and achievement in the Life Sciences Industry. 

  • 19 October 2018

GammaDelta Therapeutics, formed in 2016 by Abingworth with support from Cancer Research UK's Commercial Partnerships Team (previously known as CRT), received the 2018 Outstanding Achievement Award. GammaDelta Therapeutics was founded on research part funded by Cancer Research UK, led by Professor Adrian Hayday and Dr Oliver Nussbaumer at King’s College London and the Francis Crick Institute, into tissue resident gamma delta T cells. Gamma delta T cells are a unique class of lymphocytes that contribute to many immunological responses and diseases, and GammaDelta aim to utilise this knowledge to develop improved immunotherapies for cancer and other diseases.

Further success emerged with an additional Cancer Research-associated spinout, IGEM Therapeutics, winning the Best Start-up Biotech Company award. IGEM Therapeutics is an Immuno-Oncology Biotech that promotes development of IgE antibody drugs to fight cancer.

Notes to Editors

About Cancer Research UK

  • Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research.
  • Cancer Research UK’s pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
  • Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last 40 years.
  • Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK’s ambition is to accelerate progress so that by 2034, 3 in 4 people will survive their cancer for at least 10 years.
  • Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
  • Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured.

For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit www.cancerresearchuk.org. Follow us on Twitter and Facebook.

Related content

Breast Cancer diagnostic markers licensed by Perlegen in agreement with University of Cambrige & CRT

Perlegen Sciences, Inc., The University of Cambridge, Cancer Research Technology Ltd (CRT) and its parent organization, Cancer Research UK, announced today that Perlegen has obtained an exclusive commercial license from Cambridge Enterprise Limited, the commercialisation office of Cambridge University, to the breast cancer markers identified through collaborative research between the parties that was previously announced in February, 2005.